INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 419m ago
HOUSE PTR19m ago
SEC 13F19m ago
ROBINHOOD CHAIN18m ago
HOUSE PTR/PurchaseVerified data

Gilbert Ray Cisneros, Jr. bought ARQT

Self · Arcutis Biotherapeutics, Inc. · Arcutis Biotherapeutics, Inc. - Common stock

Side
BUY
Value range
$1,001 – $15K
Shares
Not disclosed
Price
—
Executed
May 29, 2026
Disclosed
Jun 8, 2026
Disclosure timeline10 days from execution to publication · legal deadline 45 days
May 29 executedJun 8, 2026 disclosed

ARQT · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
20/ 100 · ROUTINE
Methodology →
  • Transaction type+14 / 20

    Purchase

  • Relative size+2 / 25

    Disclosed range starting at $1K

  • Filing timing0 / 15

    Disclosed 10 days after execution (STOCK Act deadline: 45)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ARQT

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    8
    MM
    Matsuda MasaruEVP, Chief Legal Officer
    ARQTArcutis Biotherapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$39K
    1,219 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    30
    WT
    Watanabe ToddDirector, See Remarks
    ARQTArcutis Biotherapeutics, Inc.
    Open-market sale
    		SELL$139K
    4,377 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    24
    BP
    Burnett PatrickEVP, Chief Medical Officer
    ARQTArcutis Biotherapeutics, Inc.
    Open-market sale
    		SELL$30K
    943 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    0
    MM
    Matsuda MasaruEVP, Chief Legal Officer
    ARQTArcutis Biotherapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    40.0K sh
    		Nov 4, 2026Nov 4, 2026
    traded Nov 4, 2026
    		+0dSEC FORM 4

    Evidence

    25
    MM
    Matsuda MasaruEVP, Chief Legal Officer
    ARQTArcutis Biotherapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1.37M
    40.0K sh
    		Nov 4, 2026Nov 4, 2026
    traded Nov 4, 2026
    		+0dSEC FORM 4

    Evidence

    3
    MM
    Matsuda MasaruEVP, Chief Legal Officer
    ARQTArcutis Biotherapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$146K
    40.0K sh
    		Nov 4, 2026Nov 4, 2026
    traded Nov 4, 2026
    		+0dSEC FORM 4

    Evidence

    15
    SA
    Scott Robert ADirector
    ARQTArcutis Biotherapeutics, Inc.
    Grant or award
    		A—
    20.5K sh
    		Oct 23, 2026Oct 28, 2026
    traded Oct 23, 2026
    		+5dSEC FORM 4

    Evidence

    15
    SA
    Scott Robert ADirector
    ARQTArcutis Biotherapeutics, Inc.
    Grant or award
    		A—
    2,819 sh
    		Oct 23, 2026Oct 28, 2026
    traded Oct 23, 2026
    		+5dSEC FORM 4

    Evidence

    15
    SA
    Scott Robert ADirector
    ARQTArcutis Biotherapeutics, Inc.
    Grant or award
    		A—
    8,663 sh
    		Oct 23, 2026Oct 28, 2026
    traded Oct 23, 2026
    		+5dSEC FORM 4

    Evidence

    1
    MM
    Matsuda MasaruSee Remarks
    ARQTArcutis Biotherapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$92K
    3,674 sh
    		Sep 16, 2026Sep 18, 2026
    traded Sep 16, 2026
    		+2dSEC FORM 4

    Evidence

    10
    MM
    Matsuda MasaruSee Remarks
    ARQTArcutis Biotherapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$250K
    9,989 sh
    		Sep 8, 2026Sep 10, 2026
    traded Sep 8, 2026
    		+2dSEC FORM 4

    Evidence

    20
    CT
    Curran TerrieDirector
    ARQTArcutis Biotherapeutics, Inc.
    Option exercise
    		M$84K
    11.1K sh
    		Aug 27, 2026Aug 28, 2026
    traded Aug 27, 2026
    		+1dSEC FORM 4

    Evidence

    9
    CT
    Curran TerrieDirector
    ARQTArcutis Biotherapeutics, Inc.
    Option exercise
    		M—
    27.1K sh
    		Aug 27, 2026Aug 28, 2026
    traded Aug 27, 2026
    		+1dSEC FORM 4

    Evidence

    9
    CT
    Curran TerrieDirector
    ARQTArcutis Biotherapeutics, Inc.
    Option exercise
    		M—
    11.1K sh
    		Aug 27, 2026Aug 28, 2026
    traded Aug 27, 2026
    		+1dSEC FORM 4

    Evidence

    24
    CT
    Curran TerrieDirector
    ARQTArcutis Biotherapeutics, Inc.
    Option exercise
    		M$233K
    27.1K sh
    		Aug 27, 2026Aug 28, 2026
    traded Aug 27, 2026
    		+1dSEC FORM 4

    Evidence

    44
    CT
    Curran TerrieDirector
    ARQTArcutis Biotherapeutics, Inc.
    Open-market sale
    		SELL$677K
    27.1K sh
    		Aug 27, 2026Aug 28, 2026
    traded Aug 27, 2026
    		+1dSEC FORM 4

    Evidence

    40
    CT
    Curran TerrieDirector
    ARQTArcutis Biotherapeutics, Inc.
    Open-market sale
    		SELL$279K
    11.1K sh
    		Aug 27, 2026Aug 28, 2026
    traded Aug 27, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BP
    Burnett PatrickSee Remarks
    ARQTArcutis Biotherapeutics, Inc.
    Option exercise
    		M$30K
    8,300 sh
    		Aug 11, 2026Aug 13, 2026
    traded Aug 11, 2026
    		+2dSEC FORM 4

    Evidence

    24
    BP
    Burnett PatrickSee Remarks
    ARQTArcutis Biotherapeutics, Inc.
    Open-market sale
    		SELL$220K
    8,300 sh
    		Aug 11, 2026Aug 13, 2026
    traded Aug 11, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BP
    Burnett PatrickSee Remarks
    ARQTArcutis Biotherapeutics, Inc.
    Option exercise
    		M$24K
    6,700 sh
    		Aug 12, 2026Aug 13, 2026
    traded Aug 12, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    House Periodic Transaction Report
    Publisher
    Clerk of the U.S. House of Representatives
    Document ID
    20034713

    Timestamps

    Event (reported)
    May 29, 2026
    Published
    Jun 8, 2026
    Ingested by INSIDER
    Nov 5, 00:34 UTC
    Last re-read
    Nov 5, 06:47 UTC

    Extracted facts

    Filer
    Gilbert Ray Cisneros, Jr.
    Role
    Self
    Transaction
    PurchaseAs filed: “P”
    Asset
    Arcutis Biotherapeutics, Inc. - Common stock
    Ticker
    ARQT
    Reported value
    $1,001 – $15KAs filed: “$1,001 - $15,000”
    Execution date (reported)
    May 29, 2026
    Notification date (reported)
    Jun 5, 2026
    Days from execution to publication
    10

    Calculation

    Midpoint = (low + high) / 2. Used only to rank and sum ranges; the true value can be anywhere in the range.

    • Low: $1,001
    • High: $15,000

    = $8,001

    What this establishes

    Gilbert Ray Cisneros, Jr. reported a purchase of Arcutis Biotherapeutics, Inc. - Common stock. Members report a value range, not an exact amount, and do not report share counts or prices. Dates are as entered by the filer. A trade report is not evidence of wrongdoing.

    Extraction

    Method
    PDF text extraction
    Confidence
    1.00
    Self
    Gilbert Ray Cisneros, Jr.bioguide:C001123
    Issuer
    Arcutis Biotherapeutics, Inc.cik:0001787306

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.